Patient P-02209

Synthetic patientMETA-24 · Day 135 · 35–44 · F · baseline S12Steering view · 3D Open companion preview

Therapy response

Unstable

Tolerance

Deteriorating

GI state

Stable

Inflammatory state

Stable

Nutritional resilience

Stable

Discontinuation risk

54%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 META-24 started — Baseline state S12
Day 27 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 73 SC-12 recommended — Supportive Compound SC-12
Day 74 Patient accepted — Started SC-12 in the companion
Day 77 GI-04 recommended — GI Support Protocol GI-04
Day 78 Patient accepted — Started GI-04 in the companion
Day 80 GI symptom burden −19% vs expected — Supportive Compound SC-12
Day 86 GI symptom burden −21% vs expected — GI Support Protocol GI-04
Day 86 Tolerance state changed — Unstable → Improving
Day 92 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 27.

Primary contributors, last 14 days

Toxicity+8
Nutritional resilience+3
GI instability+2

What helped?

Supportive Compound SC-12Day 73
Result: symptom burden −19%
GI Support Protocol GI-04Day 77
Result: symptom burden −21%

LIFE OS recommendation

Monitoring Escalation ME-01

77%

probability of meaningful tolerance improvement

284 similar trajectories
100% showed improvement
median effect visible after 3 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

Active minutes

Wearable

27 min

worsening · -2.8 vs previous 14 d

Sleep duration

Wearable

6.1 h

stable · -0.1 vs previous 14 d

Energy level

Daily log

3.8/10

stable · -0.1 vs previous 14 d

Steps

Wearable

2,647

worsening · -366 vs previous 14 d

GI burden

Companion

47.2/100

stable · +1.3 vs previous 14 d

Adherence

Companion

52.3 %

worsening · -8.1 vs previous 14 d

Sleep quality

Wearable

22.9/100

worsening · -1.9 vs previous 14 d

Glucose, CGM daily mean

CGM

144 mg/dL

stable · +1.1 vs previous 14 d

This trajectory is decaying — what would help, what would not

Steering view →

Heading towards failing · 31 from the failing basin, 58 from restoration.

Would help

ME-01 Monitoring Escalation
100% improved among 42 similar · onset 3 d · confidence 65%
NP-02 Dietary Support Protocol
59% improved among 32 similar · onset 10 d · confidence 65%
CR-01 Clinician Review
100% improved among 6 similar · onset 5 d · confidence 65%
More protein
GI -4.3 next day on high-intake days · n 21

Would not help

Keep ultra-processed low
GI +3.8 next day on high-intake days · n 18
Keep fat low
GI +3.7 next day on high-intake days · n 17
Keep simple carbs low
GI +2.7 next day on high-intake days · n 21

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Protein
-4.3supporter · 95%
Ultra-processed food
+3.8detractor · 95%
Dietary fat load
+3.7detractor · 95%
Simple carbohydrates
+2.7detractor · 91%
Alcohol
+1no signal · 28%
Histamine load
+0.2no signal · 15%
Caffeine
+0.2no signal · 15%
Insoluble fibre
0no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Inflammatory signalling ↑85
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 48
- WearableHRV 20 ms, trending down
Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 37/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Autonomic recovery ↓65
- WearableResting HR 78 bpm
- Wearable2,647 steps/day
- WearableShort sleep window
Mucosal barrier integrity ↓30
- Daily logGI symptom score 47 and rising
- WearableSleep 6.1 h, below personal baseline
Drug metabolism and exposure ↑20
- BloodToxicity index 42

DNA

Fictional pharmacogenomic panel

IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Rapid metabolizer
Expected exposure

Microbiome

Shannon diversity 2.9 · butyrate capacity 37/100

Akkermansia muciniphilaNormal
Faecalibacterium prausnitziiLow
Bacteroides fragilisHigh
Bifidobacterium longumNormal
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 23 ms
Sleep: 6.5 h
Steps: 2,664
Resting HR: 79 bpm

Daily log: GI score 47, nutritional resilience 49, adherence 52.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Eat slowly and stop at comfortable fullness — smaller volume, more often

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the dose at the same time relative to your evening meal
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-02409	36%	S01	SC-12	no change	54
P-02018	34%	S01	GI-04	improved	46
P-02410	32%	S01	GI-04	improved	55
P-02054	31%	S01	CR-01	improved	57
P-02307	25%	S01	—	—	55
P-02598	25%	S01	—	—	53
P-02041	23%	S01	—	—	27
P-02087	23%	S01	BR-03	no change	40
P-02276	23%	S01	—	—	57
P-02568	23%	S01	—	—	51
P-02550	22%	S01	—	—	70
P-02674	34%	S02	NP-02	improved	48